backgroundaim
follow
lead
optim
set
substitut
imidazopyridin
identifi
potent
select
inhibitor
vitro
hcv
replic
particular
characterist
one
potent
compound
seri
methyl
pyridin
studi
method
antivir
activ
evalu
hcv
subgenom
replicon
genotyp
genotyp
infecti
system
replicon
resist
variou
select
hcv
inhibitor
combin
studi
select
hcv
inhibitor
perform
result
fifti
percent
effect
concentr
inhibit
hcv
subgenom
replicon
replic
rang
nm
higher
hcv
genotyp
viru
cytostat
concentr
lm
thu
result
select
indic
retain
wildtyp
activ
hcv
replicon
resist
either
hcv
proteas
inhibitor
sever
polymeras
inhibitor
combin
either
interferon
ribavirin
nucleosid
polymeras
proteas
inhibitor
result
overal
addit
antivir
activ
combin
contain
prove
highli
effect
clear
hepatoma
cell
hcv
conclus
potent
vitro
inhibitor
hcv
replic
either
alon
combin
select
hcv
inhibitor
estim
million
peopl
worldwid
chronic
infect
hcv
thu
increas
risk
develop
liver
cirrhosi
hepatocellular
carcinoma
liver
failur
endstag
liver
diseas
current
standard
therapi
ie
pegyl
interferon
combin
ribavirin
associ
signific
sideeffect
moreov
sustain
virolog
respons
depend
genotyp
obtain
patient
henc
urgent
need
new
potent
select
safe
drug
treatment
hcv
infect
sever
potent
select
inhibitor
hcv
replic
target
proteas
rnadepend
rna
polymeras
rdrp
develop
recent
year
viral
cellular
target
cyclophylin
involv
hcv
lifecycl
also
explor
efficaci
number
inhibitor
studi
patient
chronic
infect
hcv
nucleosid
nonnucleosid
inhibitor
hcv
rdrp
report
nucleosid
hcv
polymeras
inhibitor
act
prematur
chain
termin
follow
convers
triphosph
metabolit
incorpor
viral
genom
cmethylcytidin
cmecyt
first
nucleosid
hcv
inhibitor
enter
clinic
studi
develop
compound
discontinu
light
modest
antivir
efficaci
along
signific
gastrointestin
side
effect
efficaci
prodrug
azidocytidin
current
evalu
combin
standard
therapi
cmethylcytidin
prodrug
demonstr
promis
efficaci
phase
studi
chronic
infect
patient
variou
nonnucleosid
inhibitor
class
hcv
rdrp
includ
benzimidazol
indol
thiophenebas
carboxyl
acid
phenylalanin
dihydropyranon
pyranoindol
prolin
sulfonamid
benzothiadiazin
benzyliden
deriv
acryl
acid
report
optim
pursu
clinic
develop
stop
seriou
advers
effect
efficaci
benzofuran
nonnucleosid
rdrp
inhibitor
demonstr
infect
patient
clinic
develop
stop
potenti
hepatotox
new
nonnucleosid
acid
inhibitor
rdrp
caus
log
decreas
hcv
rna
day
treatment
hcvinfect
patient
gener
welltoler
earli
clinic
studi
recent
report
novel
class
substitut
imidazopyridin
capabl
select
inhibit
hcv
replic
analogu
pyridin
serv
start
point
lead
optim
result
discoveri
seri
highli
potent
inhibitor
vitro
hcv
replic
report
antihcv
activ
particular
characterist
activ
optim
analogu
methyl
pyridin
synthesi
initi
lead
compound
ie
methyl
pyridin
bpip
report
earlier
lead
optim
process
synthesi
pyridin
report
elsewher
refer
compound
sch
azidocytidin
cmecyt
synthes
report
ribavirin
purchas
icn
pharmaceut
costa
mesa
california
recombin
ifna
purchas
schere
plough
kenilworth
nj
usa
huh
cell
carri
subgenom
hcv
replicon
wt
huh
huh
kindli
provid
r
bartenschlag
univers
heidelberg
heidelberg
germani
replicon
similar
genet
makeup
huh
replicon
replic
differ
cell
clone
ii
carri
differ
adapt
mutat
iii
replicon
replic
inhibit
ifnc
rel
independ
cell
prolifer
cell
grown
dulbecco
modifi
eagl
medium
dmem
gibco
merelbek
belgium
supplement
heatinactiv
foetal
calf
serum
integro
zaandam
netherland
mem
non
essenti
amino
acid
solut
without
lglutamin
gibco
iu
penicillinml
lg
streptomycinml
gibco
mgml
select
antibiot
gibco
huh
lgml
huh
cell
huhlunet
cell
cultur
without
replicon
resist
proteas
inhibitor
nucleosid
polymeras
inhibitor
azidocytidin
cmecyt
nonnucleosid
rdrp
inhibitor
benzothiadiazin
gener
select
pressur
use
increas
concentr
respect
compound
huh
huh
cell
seed
densiti
cell
per
well
cell
cultur
plate
huh
iwaki
asahi
techno
glass
japan
tissu
cultur
treat
white
view
plate
huh
packard
canberra
canada
complet
dmem
without
antivir
assay
carri
report
earlier
readout
huh
cell
luciferas
assay
quantif
viral
rna
huh
perform
mean
realtim
pcr
huh
cell
ec
defin
concentr
compound
reduc
firefli
luciferas
signal
huh
cell
concentr
compound
reduc
amount
hcv
rna
chimer
hcv
report
viru
construct
infecti
viru
stock
gener
transfect
vitro
transcrib
rna
huhlunet
cell
harvest
cultur
medium
transfect
cell
test
antivir
activ
compound
chimer
viru
huhlunet
cell
plate
cell
per
well
infect
viru
moi
serial
dilut
compound
ad
three
day
incub
medium
remov
cell
wash
pb
lyse
use
lysi
buffer
contain
triton
viral
replic
monitor
measur
renilla
luciferas
activ
accord
manufactur
protocol
promega
madison
wi
rna
extract
realtim
quantit
rtpcr
antivir
data
fit
logist
dose
respons
equat
xb
c
use
xlfit
softwar
idb
emmeryvil
ca
ec
valu
calcul
result
equat
describ
previous
repliconcontain
cell
huh
huh
seed
densiti
cell
per
well
complet
dmem
without
cytotox
concentr
cc
defin
concentr
inhibit
prolifer
exponenti
grow
cell
determin
use
mtspm
method
previous
describ
effect
drugdrug
combin
studi
cell
replicon
replic
larg
independ
cell
prolifer
import
plan
combin
studi
cytostat
drug
ribavirin
cell
seed
complet
dmem
without
compound
ad
cell
cell
cultur
plate
checkerboard
format
combin
pair
compound
least
perform
three
independ
experi
data
evalu
use
method
prichard
shipman
briefli
theoret
addit
effect
calcul
doserespons
curv
individu
compound
equat
z
x
x
x
repres
inhibit
produc
compound
repres
compound
z
repres
effect
produc
combin
compound
compound
theoret
addit
surfac
subtract
actual
experiment
surfac
result
horizont
surfac
equal
zero
plane
combin
addit
data
point
zero
plane
indic
synergist
activ
data
point
lower
zero
plane
indic
antagonist
activ
huh
cell
seed
cm
cultur
flask
cell
densiti
cell
per
condit
sampl
huh
cell
collect
rlt
buffer
rneasi
mini
kit
qiagen
clearanc
sampl
store
use
cell
cultur
h
standard
cell
cultur
medium
contain
mgml
replac
medium
contain
either
antivir
drug
variou
concentr
ifna
cmecyt
condit
absenc
cell
incub
confluenc
reach
cell
subsequ
subcultur
densiti
per
cm
cultur
flask
contain
concentr
antivir
drug
without
clearanc
c
x
subcultur
cultur
medium
contain
mgml
absenc
antivir
drug
rebound
r
x
everi
subcultur
step
sampl
cell
lyse
rlt
buffer
store
collect
sampl
rna
extract
sampl
analyz
quantit
realtim
pcr
hcv
replicon
content
realtim
rtpcr
valu
assay
sampl
normal
nodrug
control
passag
cell
cultur
clearanc
rebound
condit
passag
passag
respect
cell
lost
replicon
die
presenc
rebound
cell
still
contain
replicon
abl
surviv
pressur
recent
report
identif
novel
class
imidazo
pyridin
potent
inhibitor
vitro
pestiviru
replic
introduct
fluorin
posit
phenyl
lead
antipestiviru
compound
methyl
pyridin
bpip
result
molecul
exhibit
antibvdv
also
antihcv
activ
compound
ec
hcv
lm
cc
lm
fig
introduct
two
fluorin
ring
analogu
compound
result
molecul
prove
potent
hcv
compound
retain
antibvdv
activ
attempt
optim
antihcv
activ
class
compound
set
analogu
modif
substitu
residu
exampl
introduct
trifluoromethyl
compound
synthes
result
compound
increas
antihcv
activ
compar
compound
interestingli
wherea
modif
result
increas
antihcv
activ
rel
littl
effect
bvdv
activ
subsequ
set
analogu
extens
modif
posit
synthes
data
shown
result
identif
seri
analogu
highli
potent
low
nm
rang
antihcv
activ
one
ie
methyl
pyridin
select
character
vitro
antihcv
activ
compound
inhibit
hcv
genotyp
subgenom
replicon
replic
mean
ec
valu
rang
nm
dosedepend
manner
tabl
fig
prove
markedli
potent
proteas
inhibitor
sch
nucleosid
polymeras
inhibitor
cmecyt
azidocytidin
nonnucleosid
polymeras
inhibitor
inhibit
replic
cell
culturegrown
chimer
hcv
hcvcc
genotyp
design
dosedepend
manner
although
less
effici
replic
genotyp
replicon
antivir
activ
viru
howev
compar
activ
refer
proteas
polymeras
inhibitor
studi
also
inhibit
bvdv
replic
although
less
potent
compound
fig
compound
prove
inact
yellow
fever
viru
anoth
member
flavivirida
famili
well
panel
virus
unrel
hcv
human
immunodefici
viru
herp
simplex
viru
influenza
viru
b
vaccinia
viru
vesicular
stomat
viru
respiratori
synciti
viru
coxsacki
viru
parainfluenza
viru
reoviru
sindbi
viru
felin
coronaviru
punta
toro
viru
data
shown
activ
evalu
panel
drugresist
replicon
combin
experi
perform
repliconcontain
cell
replicon
replic
larg
independ
cell
prolifer
import
sinc
refer
drug
cmecyt
ribavirin
concentr
use
inhibit
host
cell
prolifer
combin
checkerboard
format
either
ifna
ribavirin
cmecyt
data
analyz
use
method
prichard
shipman
combin
result
overal
addit
antivir
activ
fig
slight
synergist
effect
observ
combin
low
concentr
ifna
potenti
alon
combin
either
proteas
inhibitor
nucleosid
poli
meras
inhibitor
cmecyt
ifna
cure
hepatoma
cell
replicon
evalu
use
concentr
five
time
ec
result
rapid
profound
drop
replicon
level
achiev
complet
clearanc
huh
cell
replicon
follow
passag
presenc
either
drug
fig
contrast
combin
ec
ec
result
clearanc
huh
cell
replicon
follow
one
passag
fig
combin
ec
either
iuml
ifna
fig
f
cmecyt
ec
fig
result
clearanc
replicon
rna
follow
passag
combin
compound
pressur
fig
h
neither
cmecyt
alon
ec
result
clearanc
wherea
ifna
passag
furthermor
repliconcontain
huh
cell
surviv
rebound
condit
ie
addit
follow
cmecyt
treatment
contain
drug
resist
replicon
data
shown
addit
clearanc
capac
combin
ec
ec
cmecyt
compar
ec
either
compound
fig
clearanc
replicon
huh
cell
observ
passag
combin
ec
wherea
either
compound
alon
fail
achiev
clearanc
ec
basic
ph
acid
solut
ph
remain
stabl
nadphdepend
metabol
stabil
predict
hepat
clearanc
determin
human
dog
rat
hepat
microsom
vitro
accord
standard
method
microsom
halftim
min
human
min
dog
min
rat
hepat
microsom
predict
hepat
clearanc
lhkg
human
lhkg
dog
lhkg
rat
microsom
recent
report
antipestiviru
activ
novel
class
imidazopyridin
initi
devoid
antihcv
activ
introduct
fluorin
posit
phenyl
group
lead
compound
result
compound
vitro
antihcv
activ
optim
result
discoveri
trifluoromethyl
benzyl
pyridin
inhibit
hcv
replic
ec
nm
seri
broader
modif
group
substitut
pyridin
perform
result
seri
molecul
highli
potent
antihcv
activ
within
seri
pyridin
select
character
prove
particularli
effect
genotyp
replicon
system
use
optim
antivir
potenc
ec
valu
low
nanomolar
rang
also
inhibit
replic
genotyp
cell
cultur
infecti
hcvcc
less
effici
genotyp
replicon
antihcv
activ
compar
hcv
inhibitor
includ
ribavirin
proteas
inhibitor
sch
nucleosid
polymeras
inhibitor
cmecyt
azidocytidin
nonnucleosid
polymeras
benzothiadiazin
inhibitor
antihcv
activ
superior
compound
retain
wildtyp
antivir
activ
panel
replicon
resist
variou
hcv
inhibitor
includ
proteas
nucleosid
nonnucleosid
polymeras
inhibitor
remark
retain
signific
antivir
activ
pestiviru
bvdv
prove
also
crossresist
antibvdv
assay
bpip
one
parent
compound
class
compound
potent
antipestiviru
activ
antihcv
activ
bpip
shown
target
fingertip
pestiviru
rna
depend
rna
polymeras
remark
given
nonnucleosid
analogu
abl
inhibit
pestivirus
hcv
repres
imidazopyridin
best
knowledg
first
class
nonnucleosid
molecul
abl
inhibit
replic
pestiand
hepacivirus
albeit
potenti
differ
mechan
action
may
involv
detail
studi
molecular
mechan
action
imidazopyridin
report
elsewher
replicon
resist
gener
follow
sever
month
select
vitro
pressur
data
shown
comparison
sever
statc
inhibitor
genet
barrier
achiev
high
level
resist
rel
high
might
explain
fact
three
mutat
requir
rnadepend
rna
polymeras
gene
achiev
resist
like
specif
target
antivir
therapi
compound
statc
initi
year
becom
avail
treatment
hcv
infect
patient
combin
current
standard
therapi
later
stage
two
potent
statc
inhibitor
differ
resist
profil
may
hope
combin
without
need
interferon
andor
ribavirin
henc
import
obtain
inform
antivir
efficaci
particular
combin
reason
studi
antivir
activ
combin
class
hcv
inhibitor
end
two
differ
assay
system
employ
first
assay
combin
antivir
activ
evalu
regular
antivir
assay
ie
readout
day
incub
replicon
contain
cell
antivir
drug
combin
studi
result
overal
addit
antivir
activ
line
expect
compound
like
interfer
other
metabol
mechan
action
result
addit
antivir
effect
combin
compound
interfer
other
biolog
activ
may
either
result
synergist
antagonist
antivir
activ
exampl
impdehydrogenas
inhibitor
ribavirin
abl
potenti
antiherp
antihbv
activ
purin
base
deoxynucleosid
analogu
one
hand
result
antagonist
effect
hiv
hcv
replic
combin
pyrimidin
ribonucleosid
analogu
particular
interfer
ribavirin
purin
pyrimidin
metabol
explan
observ
antagonist
synergist
activ
note
combin
select
inhibitor
hcv
replic
howev
short
antivir
assay
may
necessarili
predict
antivir
effect
either
singl
compound
combin
thereof
therefor
studi
antihcv
activ
alon
combin
either
interferon
proteas
polymeras
hcv
inhibitor
clearanc
rebound
assay
replicon
contain
cell
cultur
one
passag
presenc
antivir
drug
absenc
select
marker
geneticin
neither
drug
concentr
higher
ec
valu
abl
achiev
clearanc
except
passag
presenc
iu
interferon
surprisingli
despit
fact
synergist
activ
note
regular
day
antivir
assay
contain
combin
ec
effici
clear
cell
replicon
clearancerebound
experi
may
possibl
predict
valu
estim
potenti
drug
combin
thereof
clear
liver
cell
replic
viru
combin
imidazopyridin
variou
statc
inhibitor
interferon
may
potenti
achiev
rapid
viral
clearanc
data
also
indic
regular
short
term
antivir
combin
assay
replicon
base
system
may
necessarili
predict
synergist
antivir
effect
follow
longterm
cultur
conclus
follow
lead
optim
seri
highli
potent
hcv
inhibitor
develop
consid
prototyp
exhibit
favor
pharmacokinet
properti
vitro
interestingli
sever
compound
seri
activ
hcv
pestivirus
current
studi
whether
common
mechan
respons
antivir
activ
whether
precis
molecular
mechan
action
antihcv
antipestiviru
activ
differ
